Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324324 · ClinicalTrials.gov registry record · Phase 3
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
A Phase 3 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00324324 is a Phase 3 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 240 participants.
The verdict
NCT00324324, a Phase 3 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
RATIONALE: A donor stem cell transplant can lower the body's immune system, making it difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently undergone donor stem cell transplant. It is not yet known whether moxifloxacin is more effective than a placebo in preventing bacterial infections in patients who have recently undergone donor stem cell transplant. PURPOSE: This randomized phase III trial is studying moxifloxacin to see how well it works compared with a placebo in preventing bacterial infections in patients who have recently undergone donor stem cell transplant.
Interventions
- DRUG Placebo
- DRUG moxifloxacin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2006-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324324
The ClinicalTrials.gov registry entry for NCT00324324 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00324324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324324 about?
NCT00324324 is a clinical study titled "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant". RATIONALE: A donor stem cell transplant can lower the body's immune system, making it difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently undergone donor stem cell transplant. It is not yet known whether moxi...
What is the current status of trial NCT00324324?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2006-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00324324?
The interventions under investigation include: Placebo (DRUG), moxifloxacin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00324324?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.